Earlier this month, thousands of healthcare professionals, scientists, and patients gathered together in Chicago to hear the latest scientific breakthroughs redefining cancer care at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

Over the course of this five-day conference, hundreds of researchers provided much-anticipated clinical and treatment updates that can help cancer patients regain their sense of self. Of these breakthroughs, one study specifically focused on reducing the most common debilitating symptom for neuroendocrine tumor (NET) patients: diarrhea.

More than 100,000 people in the U.S. live with neuroendocrine cancers and many suffer from long-term, chronic diarrhea – sometimes seen up to 20 times a day. Not only do NET patients suffer from the physical aspects of diarrhea, but it also takes an enormous social and emotional toll on patients. Many people limit their social involvements and feel isolated. With patients living for many years with this disease, there is a large unmet need for solutions that can reduce the frequency of diarrhea, so patients can start to live their life again.

Researchers at the University of Kentucky Markey Cancer Center conducted a pilot study to see if a glucose-free, amino acid oral rehydration solution, called enterade®, could reduce diarrhea frequency in NET patients. Patients drank an 8 oz bottle of enterade twice/day for one week. Data was available on 23 patients at the time of abstract submission. Results showed:

● 73% (17/23) of NET patients reported improvement in diarrhea ● 52% (12/23) reported more than 50% reduction in diarrhea frequency

These results are a big deal for NET patients, who are looking for solutions that can be incorporated into their everyday life. According to Aman Chauhan, MD, Hematology and Oncology Fellow at the University of Kentucky: “This study shows that enterade can be an effective alternative for patients with NET-related diarrhea, who need better treatment options. The proprietary combination of critical amino acids and electrolytes in enterade uniquely addresses the core contributors to NET-related diarrhea, dehydration, and compromised GI functioning.”

For NET patients, enterade can lead to a marked improvement in overall quality of life and a healthier gastrointestinal (GI) system – and it’s available without a prescription and no sugar to cause further GI dysfunction. The Markey Cancer Center will continue to share updated results at future scientific conferences over the next several months to help raise awareness of innovative solutions that can help people living with NETs regain their freedom.

Enterade is available at www.enterade.com or www.amazon.com and to learn more about how enteradeworks,check out this short video. Click here to view the actual [study] presented at ASCO 2018.

This post was originally published on HealingNET